Analysts forecast that Ra Pharmaceuticals (NASDAQ:RARX) will post earnings of ($0.53) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Ra Pharmaceuticals’ earnings. Ra Pharmaceuticals posted earnings per share of ($0.56) during the same quarter last year, which indicates a positive year-over-year growth rate of 5.4%. The firm is expected to announce its next quarterly earnings report on Wednesday, August 8th.
According to Zacks, analysts expect that Ra Pharmaceuticals will report full-year earnings of ($2.26) per share for the current year, with EPS estimates ranging from ($2.30) to ($2.22). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.10) per share, with EPS estimates ranging from ($2.24) to ($1.95). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.05).
A number of brokerages have recently commented on RARX. SunTrust Banks reaffirmed a “buy” rating on shares of Ra Pharmaceuticals in a research report on Thursday, March 15th. BMO Capital Markets dropped their price target on Ra Pharmaceuticals from $34.00 to $31.00 and set an “outperform” rating on the stock in a research report on Thursday, March 15th. ValuEngine cut Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Credit Suisse Group dropped their price target on Ra Pharmaceuticals from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $19.50.
Shares of NASDAQ RARX traded down $0.05 during trading on Thursday, reaching $6.22. 80,425 shares of the stock traded hands, compared to its average volume of 110,187. Ra Pharmaceuticals has a 52-week low of $4.78 and a 52-week high of $25.63. The stock has a market capitalization of $200.83 million, a PE ratio of -2.58 and a beta of 2.05.
A number of institutional investors and hedge funds have recently modified their holdings of RARX. Wells Fargo & Company MN lifted its holdings in Ra Pharmaceuticals by 166.2% during the 3rd quarter. Wells Fargo & Company MN now owns 23,842 shares of the company’s stock worth $348,000 after purchasing an additional 14,885 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its holdings in Ra Pharmaceuticals by 30.2% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 151,000 shares of the company’s stock worth $1,284,000 after purchasing an additional 35,000 shares in the last quarter. BlackRock Inc. lifted its holdings in Ra Pharmaceuticals by 47.9% during the 4th quarter. BlackRock Inc. now owns 952,580 shares of the company’s stock worth $8,097,000 after purchasing an additional 308,452 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Ra Pharmaceuticals by 76.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 28,937 shares of the company’s stock worth $246,000 after purchasing an additional 12,516 shares in the last quarter. Finally, Ellington Management Group LLC purchased a new stake in Ra Pharmaceuticals during the 4th quarter worth about $297,000. 47.89% of the stock is currently owned by institutional investors and hedge funds.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.